Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The EAEU region has seen a significant increase in the demand for bronchodilator drugs in recent years.
Customer preferences: The rising prevalence of respiratory diseases in the EAEU region has led to an increased demand for bronchodilator drugs. Patients suffering from respiratory diseases prefer bronchodilator drugs as they provide quick relief from symptoms such as wheezing, coughing, and shortness of breath. Moreover, the availability of different types of bronchodilator drugs such as short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), and anticholinergics has also contributed to the growth of the market.
Trends in the market: Russia is the largest market for bronchodilator drugs in the EAEU region. The Russian market is dominated by domestic manufacturers such as R-Pharm and Pharmstandard, which account for a significant share of the market. However, multinational companies such as GlaxoSmithKline and AstraZeneca also have a presence in the market. The market for bronchodilator drugs in Russia is expected to grow at a moderate pace due to the increasing prevalence of respiratory diseases and the availability of affordable generic drugs.Kazakhstan is another important market for bronchodilator drugs in the EAEU region. The market is dominated by multinational companies such as GlaxoSmithKline and AstraZeneca, which have a significant presence in the country. The market for bronchodilator drugs in Kazakhstan is expected to grow at a higher pace compared to other countries in the region due to the increasing prevalence of respiratory diseases and the growing demand for innovative drugs.
Local special circumstances: The EAEU region comprises five countries - Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan. Each country has its own regulatory framework and pricing policies, which can affect the growth of the market. For example, in Russia, the government has implemented price controls on drugs, which has led to a decrease in the prices of bronchodilator drugs. On the other hand, in Kazakhstan, the government has implemented policies to promote the use of innovative drugs, which has led to an increase in the prices of bronchodilator drugs.
Underlying macroeconomic factors: The EAEU region is characterized by a growing population, increasing urbanization, and rising disposable incomes. These factors have contributed to the growth of the healthcare sector and the demand for drugs, including bronchodilator drugs. Moreover, the region has seen an increase in the number of public-private partnerships in the healthcare sector, which has led to the development of new drugs and the expansion of the market. However, the region is also characterized by economic and political uncertainties, which can affect the growth of the market in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
